Ceralasertib - AstraZeneca/University of Pennsylvania
Alternative Names: AZD 6738Latest Information Update: 19 Jul 2024
At a glance
- Originator AstraZeneca; University of Pennsylvania
- Developer Acerta Pharma; AstraZeneca; Dana-Farber Cancer Institute; Gustave Roussy; National Cancer Institute (France); Samsung Medical Center; University of California at San Francisco; University of Pennsylvania
- Class Antineoplastics; Cyclopropanes; Imines; Ketones; Morpholines; Organic sulfur compounds; Pyridines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Cholangiocarcinoma; Gynaecological cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Phase I/II Chronic lymphocytic leukaemia
- Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Preclinical Diffuse large B cell lymphoma; Type 1 diabetes mellitus
- Discontinued Haematological malignancies; Non-Hodgkin's lymphoma; Squamous cell cancer
Most Recent Events
- 19 Jul 2024 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO), before July 2024 (AstraZeneca pipeline, July 2024)
- 19 Jul 2024 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in United Kingdom (PO), before July 2024 (AstraZeneca pipeline, July 2024)
- 19 Jul 2024 Discontinued - Phase-I for Squamous cell cancer (First-line therapy, Neoadjuvant therapy) in Taiwan (PO), before July 2024 (AstraZeneca pipeline, July 2024)